Quest Diagnostics Inc vs Sony Group Corp — how do they compare? Quest Diagnostics Inc trades at $237.64 (market cap $26.21B), while Sony Group Corp trades at $23.42 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 5.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | SONY | |
|---|---|---|
Market Cap | $26.21B | $138.43B |
Sector | Health | Technology |
52-Week High | $238.50 | $30.26 |
52-Week Low | $173.49 | $19.32 |
Enterprise Value | $31.97B | $136.35B |
Dividend Yield | 1.45% | 0.67% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Sony (SONY) trades at $23.82, up 1.53% over the past day, with a bullish technical signal from moving averages and oscillators. Recent earnings show mixed quarterly results, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. The company reported strong operating cash flow of $2.32 trillion in 2025, though net income margin turned negative at -1.75% for 2026. Positive sentiment is driven by blockbuster Spider-Man performance and a joint venture with TSMC for image sensors.
The outlook is cautiously optimistic, supported by analyst consensus with 68.75% buy ratings and a 29.75% upside potential. Key opportunities include growth in gaming and sensors, while risks involve profitability pressures and competitive threats. Investors should weigh strong cash flow against margin volatility.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →